Investigational drug · Phase 2
SNH-119014
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Thalassemia.
Phase 2Last checked: Nov 20, 2026Latest source record: May 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SNH-119014"
First trial start
2026
Jun 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SNH-119014", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thalassemia
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SNH-119014" as an intervention, largest first.
ScinnoHub Pharmaceutical Co., Ltd.Industry
NCT07087262 · 96 participants (planned) · Start Jun 27, 2025 · Primary completion Mar 28, 2026
Drug: SNH-119014; Placebo · For: Hemoglobinopathy
Sites: Hefei, China
- A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)Recruiting
ScinnoHub Pharmaceutical Co., Ltd.Industry
NCT07579949 · 30 participants (planned) · Start Jun 16, 2026 · Primary completion Sep 30, 2027
Drug: SNH-119014 dose 1; SNH-119014 dose 2 and 1 more · For: Thalassemia
Sites: Foshan, China; Guangzhou, China; Maoming, China · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- SNH-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major.
Huang Q, Huang Y, Pan L, et al. · Front Pharmacol 2026
Also in development for Thalassemia
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.